GC Green Cross Submits Phase 3 IND for Two-Dose Varicellavax Clinical Trial in Vietnam

GC Green Cross announced on November 14 that it has submitted a phase 3 clinical trial protocol (IND) for the two-dose regimen of its chickenpox vaccine, Varicellavax, to the Vietnam Ministry of Health. The company explained that it plans to complete both the clinical trial approved in Thailand in October and the new trial in Vietnam by 2027, with the goal of entering the two-dose chickenpox vaccine market in earnest starting in 2028. This Southeast Asian clinical trial will be conducted as a head-to-head comparison with Varivax, the chickenpox vaccine developed by Merck (MSD) in the United States. GC Green Cross expects this will objectively demonstrate the competitiveness of the two-dose regimen of Varicellavax. Varicellavax is a live attenuated vaccine independently developed by GC Green Cross, based on the MAV/06 strain. Notably, it is the world's first chickenpox vaccine produced without the use of antibiotics during manufacturing, which enhances safety at the time of administrati

Bio Health

11.14 09:14

Samjin Pharmaceutical Launches Fast-Acting Liquid Cold Medicine 'Lacold Syrup'

Samjin Pharmaceutical announced on November 14 that it will launch two new products for the flu season?'Lacold Total Syrup' and 'Lacold Cough Syrup'?which allow for tailored responses to patients' specific symptoms. Lacold Total Syrup contains a combination of acetaminophen (antipyretic and analgesic), guaifenesin (expectorant), DL-methylephedrine hydrochloride (antitussive), dextromethorphan (antitussive), and chlorpheniramine (antihistamine), making it effective for alleviating a wide range of cold symptoms such as fever, cough, phlegm, runny nose, and sore throat. Lacold Cough Syrup features a specialized formulation for relieving cough and phlegm, focusing on respiratory symptom relief with guaifenesin and antitussive ingredients as its main components. Notably, 'Lacold (Lock-cold)' is a syrup formulation with higher viscosity than standard liquid forms, allowing the active ingredients to stay on the throat mucosa for a longer period and thus providing more effective cough suppress

Bio Health

11.14 09:10

Daewoong Pharmaceutical Signs Export Deal for 'Enblo' with Eight Central and South American Countries, Accelerates Global Market Expansion

Daewoong Pharmaceutical announced on November 14 that it has signed export contracts for its diabetes treatment 'Enblo Tablets' (ingredient name: Enavogliflozin) with eight countries in Central and South America. The contract is valued at approximately 33.7 billion KRW, and when combined with existing agreements, the total scale reaches around 143.3 billion KRW. Daewoong Pharmaceutical, in collaboration with its partner Moksha8, has expanded its supply coverage to ten countries in Central and South America by adding new export contracts with Ecuador, Costa Rica, Guatemala, Nicaragua, Honduras, Panama, the Dominican Republic, and El Salvador to its existing agreements with Brazil and Mexico. Through this, the company plans to strengthen its presence in the Central and South American market and accelerate the diversification of its global business portfolio. The Central and South American region is a key area showing the fastest growth in the global diabetes treatment market. According t

Bio Health

11.14 08:58

"Collapse of Local Healthcare Is a System Failure... Public Medical Schools and Hospitals Are Not Fundamental Solutions"

The collapse of local healthcare is a structural issue stemming from policies centered on the Seoul metropolitan area and inadequate regional healthcare systems. Experts have suggested that it is necessary to move beyond the current healthcare policy framework based on national health insurance and establish a multi-layered regional healthcare system. The Korea Medical Biojournalists Association and the National Academy of Medicine of Korea held a media forum on November 13 at the Korea Press Center under the theme "Seeking Solutions for Building a Sustainable Local Healthcare Ecosystem," presenting policy directions focused on these issues. Cho Huisook, Head of the Public Healthcare Support Group for Gangwon Special Self-Governing Province and Professor at the Department of Healthcare Management at Kangwon National University College of Medicine, stated, "Regional hospitals lack the capacity to provide final treatment for critically ill patients. Combined with a declining population,

Bio Health

11.13 16:50

Lunit Posts Cumulative Q3 Revenue of 56.7 Billion KRW and Operating Loss of 63.4 Billion KRW

Lunit, a medical artificial intelligence (AI) company, announced on November 13 that it recorded a cumulative consolidated revenue of 56.653 billion KRW for the third quarter of this year. This represents a 66% increase compared to 34.14 billion KRW in the same period last year, marking the highest cumulative third-quarter performance since the company’s founding. Revenue for the third quarter of this year was 19.576 billion KRW, up 16.7% from 16.77 billion KRW in the same period last year. Of this, overseas sales amounted to 18.105 billion KRW, accounting for approximately 92% of total revenue, reaffirming the company’s dominance in the global market. Cumulative operating loss for the third quarter was 63.46685 billion KRW, a 32 percentage point improvement compared to 67.9472 billion KRW in the same period last year. The key driver behind this performance was the full completion of integration with Volpara, which was acquired in May last year. Volpara recorded cumulative revenue of 3

Bio Health

11.13 14:59

Yuhan Corporation to Hold 'One-Day Company Tour' for Job Seekers

Yuhan Corporation announced on November 13 that it will hold a one-day company tour at its headquarters in Daebang-dong, Dongjak-gu, Seoul, on November 19 for those seeking employment in the pharmaceutical and biotech industries. This program, organized in collaboration with the Seoul Gwanak Employment and Welfare Center of the Ministry of Employment and Labor, consists of the following: a tour of Yuhan Corporation’s corporate culture, an introduction to the company’s HR system (including talent requirements and recruitment) and corporate culture, small-group mentoring sessions with current employees from R&D and pharmaceutical sales, and a visit to the Yuhan Memorial Hall and Memorial Room. The event will take place for three hours starting at 2 p.m. on November 19, with 50 university students and recent graduates seeking employment in pharmaceutical sales and R&D positions expected to attend. This one-day company tour was organized at the suggestion of the Seoul Gwanak Employment and

Bio Health

11.13 14:38

Kwangdong Pharmaceutical Promotes Sangyoung Park to President and Chief Operating Officer

Kwangdong Pharmaceutical announced on November 13 that it has promoted Sangyoung Park, Executive Vice President, to President and Chief Operating Officer, promoted Giryong Bae, Managing Director, to Executive Director, and newly appointed Daeseok Jung, Head of Human Resources Planning Division, as Managing Director. This executive reshuffle is seen as a strategic decision aimed at securing sustainable new growth engines based on a stable management foundation, and focusing capabilities on enhancing shareholder value and external credibility. In particular, the company plans to further strengthen organizational competitiveness by expanding its R&D new drug development pipeline and advancing its human resource management system. President Sangyoung Park will oversee overall management activities as Chief Operating Officer. Park has previously served as Chief Safety and Environment Officer (CSEO) and Head of Communications, overseeing media relations, ESG, legal affairs, and audit work, w

Bio Health

11.13 13:29

Hanmi Science Expands Medical Device Business...Targeting Overseas Markets with Surgical Hemostatic Agents

Hanmi Science is accelerating the global expansion of its medical device business, including surgical therapeutic materials. Hanmi Science, the holding company of Hanmi Group, announced on the 13th that it will participate in 'MEDICA 2025,' the world's largest medical device exhibition, to be held in Dusseldorf, Germany from November 17 to 20. The company plans to showcase its medical device products and technological capabilities, while strengthening its global business at the event. At this exhibition, three types of surgical hemostatic agents developed by Teracion Biomedical, a biosurgery specialist, and exclusively licensed for overseas sales by Hanmi Science, will be unveiled. The featured products include: ▲Oozfix, an absorbable powder-type adjunctive hemostat; ▲Tableau Wax, a poloxamer-based absorbable bone hemostat; and ▲ActiClot, an active hemostat that combines thrombin with a starch-derived polymer matrix. These products represent the core lineup in Hanmi Science's medical d

Bio Health

11.13 13:27

"I Don't Even Want to Pick Up My Spoon"... Appetite Loss Arrived Like Morning Sickness [Maunjaero Report] ②

GC Green Cross Submits Phase 3 IND for Two-Dose Varicellavax Clinical Trial in Vietnam

Samjin Pharmaceutical Launches Fast-Acting Liquid Cold Medicine 'Lacold Syrup'

Daewoong Pharmaceutical Signs Export Deal for 'Enblo' with Eight Central and South American Countries, Accelerates Global Market Expansion

"Collapse of Local Healthcare Is a System Failure... Public Medical Schools and Hospitals Are Not Fundamental Solutions"

Lunit Posts Cumulative Q3 Revenue of 56.7 Billion KRW and Operating Loss of 63.4 Billion KRW

Yuhan Corporation to Hold 'One-Day Company Tour' for Job Seekers

Kwangdong Pharmaceutical Promotes Sangyoung Park to President and Chief Operating Officer

Hanmi Science Expands Medical Device Business...Targeting Overseas Markets with Surgical Hemostatic Agents

Special Coverage

In the News